Ait Addi R. Metastatic clear cell sarcoma of the pancreas: An overview. World J Clin Cases 2024; 12(29): 6262-6265 [PMID: 39417060 DOI: 10.12998/wjcc.v12.i29.6262]
Corresponding Author of This Article
Rachid Ait Addi, Doctor, PhD, Academic Editor, Associate Professor, Lecturer, Research Associate, Research Scientist, Senior Editor, Senior Researcher, Surgeon, Department of Biology, Independent Senior Researcher, 1368 Rte Essaouira, N 03, Marrakesh 40000, Morocco. dr.rachid.aitaddi@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 16, 2024; 12(29): 6262-6265 Published online Oct 16, 2024. doi: 10.12998/wjcc.v12.i29.6262
Metastatic clear cell sarcoma of the pancreas: An overview
Rachid Ait Addi
Rachid Ait Addi, Department of Biology, Independent Senior Researcher, Marrakesh 41020, Morocco
Author contributions: Ait Addi R contributed to study selection, data extraction, data synthesis, quality assessment, drafting and revision of the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rachid Ait Addi, Doctor, PhD, Academic Editor, Associate Professor, Lecturer, Research Associate, Research Scientist, Senior Editor, Senior Researcher, Surgeon, Department of Biology, Independent Senior Researcher, 1368 Rte Essaouira, N 03, Marrakesh 40000, Morocco. dr.rachid.aitaddi@gmail.com
Received: March 23, 2024 Revised: July 2, 2024 Accepted: July 10, 2024 Published online: October 16, 2024 Processing time: 157 Days and 15.8 Hours
Abstract
Clear cell sarcoma (CCS) is a rare soft-tissue sarcoma that accounts for less than 1% of all cases and was originally reported in 1965. The incidence of CCS is estimated to be approximately 0.014/100000 depending on the surveillance, epidemiology and end results databases. CCS is a highly invasive type that mainly metastasizes to the lungs, followed by the bones and brain; however, pancreatic metastasis is relatively rare. It has a high probability of recurrence or metastasis and has a poor prognosis with a high mortality rate. Finally, even after recovery, it is fundamental to keep regular postoperative follow-up for CCS patients.
Core Tip: In this editorial, we comment on a case report by Liu et al. According to the authors of this article, the objective of presenting this case was to bring to attention of metastatic clear cell sarcoma (CCS) of the pancreas. CCS is an uncommon soft-tissue sarcoma, making up less than 1% of all cases, and was first documented in 1965. The estimated incidence of CCS is around 0.014 per 100000 individuals, varying based on data from surveillance, epidemiology, and end results databases.
